{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "62-year-old man diagnosed in 2020 with T2N3M1b adenocarcinoma subtype NSCLC, KRASG12C mutant, and programmed death-ligand 1 positive at 2%. No relevant previous comorbidities, no previous history of liver disease, hepatitis, or alcohol abuse, and was positive for having cytomegalovirus immunoglobulin G.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0001637",
              "label": "Adenocarcinoma",
              "status": "active",
              "onset_date": "2020"
            },
            {
              "code": "C0684249",
              "label": "Non-Small Cell Lung Carcinoma",
              "status": "active",
              "onset_date": "2020"
            },
            {
              "code": "C0009450",
              "label": "Cytomegalovirus Infections",
              "status": "historical",
              "onset_date": null
            }
          ],
          "social_history": [
            {
              "category": "alcohol",
              "status": "never",
              "description": "no previous history of alcohol abuse"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Initially treated with carboplatin-pemetrexed-pembrolizumab, with mediastinal progression after cycle 1 of maintenance pembrolizumab-pemetrexed, for which he received palliative thoracic radiotherapy (20 Gy in 5 fractions). CPI therapy had caused no previous hepatotoxicity and no immune-related AEs worse than grade 1.",
        "clinical_data": {
          "medications": [
            {
              "drug": "carboplatin",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "pemetrexed",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "pembrolizumab",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "pembrolizumab",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "pemetrexed",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "procedures": [
            {
              "name": "radiotherapy",
              "approach": null,
              "date": null,
              "location": "thorax",
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Commenced second-line sotorasib, 960 mg once daily, on compassionate supply prelicense in March 2021, 14 weeks after the last dose of pembrolizumab, having discussed risks and alternatives.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Sotorasib",
              "dosage": "960 mg",
              "frequency": "once daily",
              "modality": "oral",
              "start_date": "2021-03",
              "end_date": null
            },
            {
              "drug": "Pembrolizumab",
              "end_date": "2021-03"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Baseline liver function tests before commencing sotorasib were within the reference range. On cycle 1 day 12, he had grade 2 alkaline phosphatase (ALP), grade 1 bilirubin, and grade 3 ALT rise. Sotorasib was held.",
        "clinical_data": {
          "labs": [
            {
              "test": "Alkaline Phosphatase Measurement",
              "value": "grade 2",
              "unit": "CTCAE grade",
              "flag": "abnormal",
              "timestamp": "cycle 1 day 12"
            },
            {
              "test": "bilirubin measurement",
              "value": "grade 1",
              "unit": "CTCAE grade",
              "flag": "abnormal",
              "timestamp": "cycle 1 day 12"
            },
            {
              "test": "Alanine Aminotransferase Measurement",
              "value": "grade 3",
              "unit": "CTCAE grade",
              "flag": "abnormal",
              "timestamp": "cycle 1 day 12"
            }
          ],
          "medications": [
            {
              "drug": "Sotorasib",
              "status": "held",
              "start_date": "before cycle 1 day 12"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Bilirubin, ALT, and ALP worsened rapidly in subsequent days, requiring commencement of 60 mg oral prednisolone on day 15 and hospitalization.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0032938",
              "dosage": "60 mg",
              "frequency": null,
              "modality": "oral",
              "start_date": "null",
              "end_date": "null",
              "indication": null
            }
          ],
          "labs": [
            {
              "test": "C0005357",
              "value": null,
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "C0001774",
              "value": null,
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "C0002027",
              "value": null,
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Liver ultrasonography, magnetic resonance cholangiopancreatography, and comprehensive acute viral serologic and molecular testing identified no other hepatotoxicity causes, including extensive testing for hepatitis A/B/C/E and a broad autoimmune antibody panel. Positive Epstein\u2013Barr virus immunoglobulin G and detection at low-level with polymerase chain reaction (346 IU/mL).",
        "clinical_data": {
          "imaging": [
            {
              "type": "Liver ultrasonography",
              "body_part": "Liver",
              "modality": "Ultrasound",
              "finding": "no other hepatotoxicity causes"
            },
            {
              "type": "Magnetic resonance cholangiopancreatography",
              "body_part": "Liver",
              "modality": "MRI",
              "finding": "no other hepatotoxicity causes"
            }
          ],
          "labs": [
            {
              "test": "Hepatitis A serologic testing",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Hepatitis B serologic testing",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Hepatitis C serologic testing",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Hepatitis E serologic testing",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Epstein\u2013Barr virus immunoglobulin G",
              "value": "positive",
              "flag": "abnormal"
            },
            {
              "test": "Epstein\u2013Barr virus polymerase chain reaction",
              "value": "346",
              "unit": "IU/mL",
              "flag": "abnormal"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient initially treated with carboplatin-pemetrexed-pembrolizumab, followed by mediastinal progression after cycle 1 of maintenance pembrolizumab-pemetrexed, leading to palliative thoracic radiotherapy (20 Gy in 5 fractions). CPI therapy had caused no previous hepatotoxicity and no immune-related AEs worse than grade 1.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0007671",
            "C0030958",
            "C4072724"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Patient commenced second-line sotorasib, 960 mg once daily, on compassionate supply prelicense in March 2021, 14 weeks after the last dose of pembrolizumab, having discussed risks and alternatives.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C4729047",
            "C4072724"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2021-03"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "On cycle 1 day 12 of sotorasib, patient developed grade 2 alkaline phosphatase (ALP), grade 1 bilirubin, and grade 3 ALT rise. Sotorasib was held.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0151829",
            "C0005357",
            "C0001774"
          ],
          "change_type": "progression",
          "target_domain": "lab",
          "timestamp": "cycle 1 day 12"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Bilirubin, ALT, and ALP worsened rapidly in subsequent days, requiring commencement of 60 mg oral prednisolone on day 15 and hospitalization.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0005357",
            "C0001774",
            "C0002027"
          ],
          "change_type": "progression",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Liver ultrasonography, magnetic resonance cholangiopancreatography, and comprehensive acute viral serologic and molecular testing identified no other hepatotoxicity causes, including extensive testing for hepatitis A/B/C/E and a broad autoimmune antibody panel. Positive Epstein\u2013Barr virus immunoglobulin G and detection at low-level with polymerase chain reaction (346 IU/mL).",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0024118",
            "C0036341"
          ],
          "change_type": "other",
          "target_domain": "imaging"
        }
      }
    }
  ]
}